Oral News and Research

RSS

New Aspen Dental office to open in Auburn, ME

Aspen Dental is proud to announce that a new Aspen Dental office is opening in Auburn, ME on Thursday, Dec. 20. Located near Wal-Mart at 791 Turner Street, the practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.

15 Dec 2012

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

15 Dec 2012

Cempra commences CEM-102 Phase 2 trial in prosthetic joint infections

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the initiation of its Phase 2 clinical trial of CEM-102 in patients with prosthetic joint infections (PJIs).

15 Dec 2012

Perthes’ disease link to congenital disorders revealed

Researchers have linked Perthes' disease with several congenital conditions, pointing to intra-uterine factors behind the development of the disease.

14 Dec 2012

Novel antibodies can aid in early diagnosis of Sjogren's Syndrome

Patients suffering from the painful autoimmune disease, Sjogren's Syndrome, will soon be able to be properly diagnosed much earlier, thanks to the discovery of novel antibodies by researchers at the University at Buffalo and Immco Diagnostics, Inc. The breakthrough, described in a paper in the December issue of Clinical Immunology, will allow patients to be treated sooner when they are much more likely to benefit.

14 Dec 2012

Viewpoints: Politicians flirting with danger on Medicare eligibility age; Maybe doctors should be paid less

The 2010 health- care law, which imposed immediate and heavy cuts on hospitals, drugmakers and insurers, left doctors relatively untouched. A 1997 law that reduces doctors' Medicare payments is consistently overridden by Congress.

14 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012

Predictor of lymph node metastasis after oral cancer unmasked

The presence of high levels of tumor-associated tissue eosinophilia in early oral squamous cell carcinoma tissue can predict future occult lymph node metastasis, study results show.

13 Dec 2012

Feds seek dismissal of contraception mandate challenge filed by Archdiocese of Atlanta

In related coverage, religious colleges involved in a separate challenge to birth control mandate will go to court this week to argue their standing to bring a lawsuit.

13 Dec 2012

Isolite Systems to offer dental isolation in Canada

Isolite Systems announced today that it will begin offering its dental isolation systems for sale in Canada. This includes the company's award-winning Isolite and Isodry dental isolation systems, and its patented single-use Isolite Mouthpieces that are used with the systems.

13 Dec 2012

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.

13 Dec 2012

Review describes current state of lung cancer care

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

12 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.

12 Dec 2012

Viewpoints: Sen. Portman's Rx for deficit talks; Gerson says Obama needs to give Boehner political cover to make a deal

Washington needs to pursue structural reforms in the country's important but unsustainable entitlement programs and in an inefficient, outdated tax code. By doing so, lawmakers can responsibly avoid the immediate cliff while addressing the long-term fiscal crisis and spurring job creation.

12 Dec 2012

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Durata Therapeutics, Inc. today announced preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

11 Dec 2012

Roundup: NH hospital at center of hepatitis outbreak details fixes; Report finds racial gap in Colo. dental coverage; Health cuts part of Conn. budget plan

Though Exeter Hospital has fixed problems discovered after a hepatitis C outbreak last spring, federal officials say the hospital initially failed to conduct an adequate investigation. The Centers for Medicare and Medicaid Services said last week it no longer plans to terminate the hospital's Medicare funding now that multiple issues raised by inspectors have been addressed.

11 Dec 2012

Lenalidomide effective alternative in lupus

The thalidomide derivative, lenalidomide, is a “safe” and effective treatment in refractory cutaneous lupus erythematosus patients, although three-quarters of patients experience clinical relapse after the drug is withdrawn, say Spanish researchers.

11 Dec 2012

High-altitude treatment may help severe asthma patients

Individuals with severe refractory asthma may benefit from high-altitude treatment, irrespective of their sensitivity to airborne allergens, suggest findings from a study conducted in the Swiss Alps.

11 Dec 2012

Oral News and Research

New Aspen Dental office to open in Auburn, ME

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Cempra commences CEM-102 Phase 2 trial in prosthetic joint infections

Perthes’ disease link to congenital disorders revealed

Novel antibodies can aid in early diagnosis of Sjogren's Syndrome

Viewpoints: Politicians flirting with danger on Medicare eligibility age; Maybe doctors should be paid less

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Predictor of lymph node metastasis after oral cancer unmasked

Feds seek dismissal of contraception mandate challenge filed by Archdiocese of Atlanta

Isolite Systems to offer dental isolation in Canada

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Review describes current state of lung cancer care

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

Viewpoints: Sen. Portman's Rx for deficit talks; Gerson says Obama needs to give Boehner political cover to make a deal

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Roundup: NH hospital at center of hepatitis outbreak details fixes; Report finds racial gap in Colo. dental coverage; Health cuts part of Conn. budget plan

Lenalidomide effective alternative in lupus

High-altitude treatment may help severe asthma patients

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News